Study to Assess the Efficacy and Safety of Emapalumab in Primary Haemophagocytic Lymphohistiocytosis
Trial · NCT03312751
Results by group464
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 464
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Response at Week 8 or End of Treatment (if Earlier) | All-treated Analysis Set | 62.9 | 95% Confidence Interval 44.9 to 78.5 | Percentage of participants | |
| Overall Response at Week 8 or End of Treatment (if Earlier) | All-treated Analysis Set - Treatment naïve | 50.0 | 95% Confidence Interval 24.7 to 75.3 | Percentage of participants | |
| Overall Response at Week 8 or End of Treatment (if Earlier) | All-treated Analysis Set - Treatment Experienced | 73.7 | 95% Confidence Interval 48.8 to 90.9 | Percentage of participants | |
| Overall Survival at End of Study | All-treated Analysis Set | Alive at end of study | 19 | Participants | |
| Overall Survival at End of Study | All-treated Analysis Set - Treatment naïve | Alive at end of study | 9 | Participants | |
| Overall Survival at End of Study | All-treated Analysis Set - Treatment Experienced | Alive at end of study | 10 | Participants | |
| Overall Survival at End of Study | All-treated Analysis Set | Early discontinuation | 1 | Participants | |
| Overall Survival at End of Study | All-treated Analysis Set - Treatment naïve | Early discontinuation | 0 | Participants | |
| Overall Survival at End of Study | All-treated Analysis Set - Treatment Experienced | Early discontinuation | 1 | Participants | |
| Overall Survival to HSCT | All-treated Analysis Set | 25 | Participants | ||
| Overall Survival to HSCT | All-treated Analysis Set - Treatment naïve | 12 | Participants | ||
| Overall Survival to HSCT | All-treated Analysis Set - Treatment Experienced | 13 | Participants | ||
| Overall Survival for Patients Receiving HSCT | All-treated Analysis Set | 17 | Participants | ||
| Overall Survival for Patients Receiving HSCT | All-treated Analysis Set - Treatment naïve | 8 | Participants | ||
| Overall Survival for Patients Receiving HSCT | All-treated Analysis Set - Treatment Experienced | 9 | Participants | ||
| Event-free Survival | All-treated Analysis Set | 16 | Participants | ||
| Event-free Survival | All-treated Analysis Set - Treatment naïve | 8 | Participants | ||
| Event-free Survival | All-treated Analysis Set - Treatment Experienced | 8 | Participants | ||
| Overall Response at Start of Conditioning | All-treated Analysis Set | Complete response | 4 | Participants | |
| Overall Response at Start of Conditioning | All-treated Analysis Set - Treatment naïve | Complete response | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03312751/results